Clinical Trial Update: Second Line Sorafenib After Pazopanib in Patients With RCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating second-line sorafenib after prior pazopanib in metastatic renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Votrient (Pazopanib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED